Vertex has a targeted strategy to market hepatitis C drug Incivek

Vertex Pharmaceuticals is designating a "highly specialized sales force" to promote Incivek, as the biotech company prepares to compete with Victrelis maker Merck & Co. in the hepatitis C market. Merck recently...[подробнее]

Study: Hepatitis C may have "jumped" from dogs to humans

HealthDay News consumer.healthday.com/Article.asp

Source: AABBsmartbrief[подробнее]

FDA OKs Telaprevir for Hep C

WASHINGTON -- The FDA has approved telaprevir (Incivek) for treatment of hepatitis C genotype 1 in combination with pegylated interferon and ribavirin, making it the second new protease inhibitor to win agency approval for the...[подробнее]

Vertex's hepatitis C drug Incivek is approved by FDA

The FDA approved Vertex Pharmaceuticals' Incivek, a hepatitis C drug intended for use with standard therapy consisting of ribavirin and pegylated interferon. The medicine, also known as telaprevir, costs $49,200 for 12 weeks of...[подробнее]

EU panel backs approval of Merck's hepatitis C drug boceprevir

A European Medicines Agency committee recommended that Merck & Co.'s boceprevir be approved for use in addition to standard interferon-based therapy for chronic hepatitis C. The drug was approved by the FDA two weeks ago as...[подробнее]

"Gene editing" technique holds promise for muscular dystrophy

Scientists at the Salk Institute for Biological Studies said they were able to replace faulty genes with healthy DNA using induced pluripotent stem cells and adult stem cells in a so-called "gene editing" technique. The...[подробнее]

Abbott gets FDA approval for hepatitis C test

Abbott said it has received FDA approval for its hepatitis C test, called RealTime HCV. The test measures levels of the virus in plasma or serum. The company said the test allows detection of very low levels of the virus so...[подробнее]